Cadila: More a COVID hedge in the near term
Cadila's India presence -- at about 45 per cent of sales -- is similar in size as the US business and provides better cash-flow visibility
Aarti Industries: Pricing power on display
Ability to quickly harness demand in the macro recovery phase and display of pricing power add to our constructive view on the Aarti Industries stock
Chemplast Sanmar IPO: More a commodity than speciality product
We would not be surprised, if, in future, the suspension PVC business of Chemplast Sanmar is once again demerged to unlock value for the standalone business
IPCA Labs: Strong revival for domestic formulations
IPCA, which was mainly known a few years ago for anti-malarial medications, is now having a significant contribution from non-anti-malarial medicines
Cipla: M&A opportunity could be near-term trigger
Cipla, with its leadership in inhalation, focus on green chemistry and potential deployment of cash savings for new growth drivers, warrants attention
Balaji Amines: Agile execution of import substitution play
We remain positive on Balaji’s strategy to focus on import substitution opportunities. In the process, the management appears nimble in implementing change in technology, process and products to edge out global competition
Krsnaa Diagnostics IPO: Should one foot the bill for this diagnostics?
The key differentiator in the business model of Krsnaa Diagnostics is the hub-and-spoke model in radiology
PI Industries: A sizeable entry into pharma
Acquisition of Ind Swift Laboratories would provide synergistic benefits and would be new growth catalyst for the company. Company believes the acquisition is the first step towards transforming itself into a more diversified player.
Sun Pharma: Ilumya illuminates
The specialty segment remains an important part of the Sun Pharma's strategy to scale up business and launch itself into the domain of complex molecules and novel dosage forms
Navin Fluorine: Speciality chemicals, CRAMS to lead the way
Navin Fluorine has mandated a large consulting firm to look at the synergistic opportunity presented by speciality chemicals and CRAMS
US Fed: Now, one step closer to 'tapering'
The Fed believes that long term inflation expectations are anchored around the 2 percent objective and that’s what matters for policy decisions
Dr Reddy’s: Growth story remains intact; margins key monitorable
Dr Reddy's margins are likely to be weighed by recurring investments - digitization, brand building exercise & elevated R&D - in near to medium term
Glenmark Life Sciences IPO: Traction in complex APIs holds re-rating potential
In order to address the opportunities in oncology, peptides and iron compounds, Glenmark Life Science plans to build an R&D pipeline in the coming years
Gland Pharma’s new product play for FY22 holds a lot of promise
While the US market is still expected to clock 18-20 per cent growth for Gland Pharma in FY22, the company’s foray into non-US markets would accelerate growth in the medium term
Rossari Biotech: Calibrated inorganic strategy opens up opportunities
Rossari’s M&A strategy is apparently focussed on encompassing complementary technology, talent, products and client base
Tatva Chintan Pharma Chem: Is the speciality chemical IPO worth applying?
Tatva has a diversified product portfolio, with a dominant position in most product segments. Valuations are at a discount to the comparable peer set
Clean Science and Technology IPO: Clean and richly valued
CSTL is among the few companies globally focussed on developing eco-friendly and cost-competitive technologies using in-house catalytic processes
Demand for medical gloves gives this stock a distinct edge
Apcotex plans to spend Rs 100-110 crore over FY22 and early FY23 if environmental permission for the XNBR latex plant at Valia comes through
Solara Active: Build-up of CRAMS pipeline to help rerate
Solara is looking at utilising cash flows to build a project pipeline for CRAMS, capitalising on inorganic opportunities
Bodal Chemicals: Benzene benefit to show up from FY24
Business diversification seems to be an attempt to reduce volatility in profitability from the dyes industry and gain exposure to more stable chemicals
Reliance’s foray into green energy will boost India’s renewable energy ambitions and geopolitical standing
RIL AGM 2021: India’s energy sector is on the cusp of a solar powered revolution and Reliance is set to play a leading role in it
India Pesticides IPO: What does this have in store for investors?
India Pesticides, with one of the best return ratios in the industry, has swiftly ramped up its capacity in recent years indicating good order book and strong linkage with formulators
US Fed meet ratchets up inflation fears and tapering talk
While the Fed Chair sounded dovish, he dropped hints of a significant change in the macroeconomic context in the last six months which may warrant tapering or rate hike earlier than expected, puncturing the equity rally
IPO radar | Is KIMS a dark horse in the making?
The growth strategy at KIMS is based on volume play driven by hinterland opportunities